Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2018 Apr 26

PMID 29693015

Citations 10

Authors

Kenta Masui

Takashi Komori

Yukinari Kato

Kenkichi Masutomi

Koichi Ichimura

Satoshi Ogasawara

Mika K Kaneko

Hiroharu Oki

Hiroyoshi Suzuki

Masayuki Nitta

Takashi Maruyama

Yoshihiro Muragaki

Takakazu Kawamata

Tatsuo Sawada

Noriyuki Shibata

Affiliations

Soon will be listed here.

Abstract

Telomerase reverse transcriptase (TERT) is important for the biology of diffuse gliomas. promoter mutations are selectively observed among 1p/19q-codeleted oligodendrogliomas and isocitrate dehydrogenase gene- wildtype glioblastoma (GBM). However, TERT transcripts range widely in various cancers including gliomas, and TERT protein expression has been rarely investigated thus far. It would be thus critical to examine the expression level of TERT in tumors in addition to its mutational status, and sensitive and specific methods are urgently needed to examine TERT protein expression for the assessment of TERT biology in gliomas. Using our newly developed TERT-specific monoclonal antibody (TMab-6) applicable to human tissue, we found an unexpected increase in TERT expression in -wildtype as well as -mutated gliomas and in tumor vasculature. This is the first extensive analysis on the expression of TERT immunoreactivity in human glioma tissue, suggesting that TERT protein expression may be regulated by several mechanisms in addition to its promoter mutation.

Citing Articles

Clinical research progress of telomerase targeted cancer immunotherapy: a literature review.

Wang Y, Zhang X, Chen G, Shao M Transl Cancer Res. 2024; 13(7):3904-3921.

PMID: 39145070 PMC: 11319969. DOI: 10.21037/tcr-24-196.

Genetic Prognostic Factors in Adult Diffuse Gliomas: A 10-Year Experience at a Single Institution.

Behrooz A, Darzi Ramandi H, Latifi-Navid H, Peymani P, Tarharoudi R, Momeni N Cancers (Basel). 2024; 16(11).

PMID: 38893240 PMC: 11172038. DOI: 10.3390/cancers16112121.

A Qualitative Signature to Identify Promoter Mutant High-Risk Tumors in Low-Grade Gliomas.

Zheng W, Zhang R, Huang Z, Li J, Wu H, Zhou Y Front Mol Biosci. 2022; 9:806727.

PMID: 35495630 PMC: 9047542. DOI: 10.3389/fmolb.2022.806727.

Detection of Promoter Mutations as a Prognostic Biomarker in Gliomas: Methodology, Prospects, and Advances.

Hasanau T, Pisarev E, Kisil O, Nonoguchi N, Le Calvez-Kelm F, Zvereva M Biomedicines. 2022; 10(3).

PMID: 35327529 PMC: 8945783. DOI: 10.3390/biomedicines10030728.

TERT expression increases with tumor grade in a cohort of -mutant gliomas.

Jalasutram A, Caniglia J, Velpula K, Guda M, Bach S, Tsung A Am J Transl Res. 2022; 14(1):295-303.

PMID: 35173846 PMC: 8829640.

References

Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T . Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol. 2013; 14(6):534-42. DOI: 10.1016/S1470-2045(13)70110-4. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A . Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015; 129(6):829-48. DOI: 10.1007/s00401-015-1432-1. View

Ohba S, Mukherjee J, Johannessen T, Mancini A, Chow T, Wood M . Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016; 76(22):6680-6689. PMC: 5290072. DOI: 10.1158/0008-5472.CAN-16-0696. View

Yamaguchi S, Maida Y, Yasukawa M, Kato T, Yoshida M, Masutomi K . Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells. PLoS One. 2014; 9(11):e112438. PMC: 4223061. DOI: 10.1371/journal.pone.0112438. View

Park C, Lee S, Kim J, Kim J, Kim T, Lee S . Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget. 2014; 5(10):3399-407. PMC: 4102818. DOI: 10.18632/oncotarget.1975. View

Komori T . Updated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathology. Brain Tumor Pathol. 2017; 34(4):139-140. DOI: 10.1007/s10014-017-0299-3. View

Maida Y, Yasukawa M, Okamoto N, Ohka S, Kinoshita K, Totoki Y . Involvement of telomerase reverse transcriptase in heterochromatin maintenance. Mol Cell Biol. 2014; 34(9):1576-93. PMC: 3993606. DOI: 10.1128/MCB.00093-14. View

Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T . Revisiting TP53 Mutations and Immunohistochemistry--A Comparative Study in 157 Diffuse Gliomas. Brain Pathol. 2014; 25(3):256-65. PMC: 8028857. DOI: 10.1111/bpa.12173. View

10.

Fujii Y, Kaneko M, Kato Y . MAP Tag: A Novel Tagging System for Protein Purification and Detection. Monoclon Antib Immunodiagn Immunother. 2016; 35(6):293-299. PMC: 5206699. DOI: 10.1089/mab.2016.0039. View

11.

Reuss D, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C . ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2014; 129(1):133-46. DOI: 10.1007/s00401-014-1370-3. View

12.

Bell R, Rube H, Kreig A, Mancini A, Fouse S, Nagarajan R . Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015; 348(6238):1036-9. PMC: 4456397. DOI: 10.1126/science.aab0015. View

13.

Schwartzentruber J, Korshunov A, Liu X, Jones D, Pfaff E, Jacob K . Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482(7384):226-31. DOI: 10.1038/nature10833. View

14.

Arita H, Narita Y, Yoshida A, Hashimoto N, Yoshimine T, Ichimura K . IDH1/2 mutation detection in gliomas. Brain Tumor Pathol. 2014; 32(2):79-89. DOI: 10.1007/s10014-014-0197-x. View

15.

Brat D, Verhaak R, Aldape K, Yung W, Salama S, Cooper L . Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015; 372(26):2481-98. PMC: 4530011. DOI: 10.1056/NEJMoa1402121. View

16.

Arita H, Narita Y, Takami H, Fukushima S, Matsushita Y, Yoshida A . TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathol. 2013; 126(6):939-41. DOI: 10.1007/s00401-013-1203-9. View

17.

Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R . Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):709-22. DOI: 10.1056/NEJMoa1308345. View

18.

Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T . mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013; 18(5):726-39. PMC: 3840163. DOI: 10.1016/j.cmet.2013.09.013. View

19.

Guilleret I, Yan P, Grange F, Braunschweig R, Bosman F, Benhattar J . Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer. 2002; 101(4):335-41. DOI: 10.1002/ijc.10593. View

20.

Ceccarelli M, Barthel F, Malta T, Sabedot T, Salama S, Murray B . Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164(3):550-63. PMC: 4754110. DOI: 10.1016/j.cell.2015.12.028. View